Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page

First patient treated in Japan with Abbott’s Absorb BVS

Friday, 19 Aug 2011 15:19
Absorb bioresorbable vascular scaffold
Absorb bioresorbable vascular scaffold

The first patient in Japan has been treated with Abbotts’ Absorb bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND global clinical trial. To date, more than 300 patients in Europe, Latin America and Asia Pacific have been enrolled in this trial.

Absorb restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant.

The first patient in Japan was treated in the ABSORB EXTEND clinical trial by Shigeru Saito, director, Cardiology and Catheterization Laboratories, and vice president, Shonan Kamakura Hospital, Kanagawa, Japan.

“Abbott’s BVS technology has the potential to open up a new therapy option for physicians treating patients with coronary artery disease in Japan,” said Saito. “For Japanese patients, this technology will hold tremendous appeal, as it is designed to treat a clogged blood vessel like a drug eluting stent and then dissolve, thereby restoring a more natural vessel function without leaving a permanent metallic implant behind in the body. Our hope is that our participation in the ABSORB EXTEND trial will be a meaningful contribution toward making this innovative technology available to patients in Japan.”

Absorb is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolving sutures. Because a permanent metallic implant is not left behind, a vessel treated with this device may ultimately have the ability to move, flex, pulsate and dilate. Restoration of these naturally occurring vessel functions is one of the features that makes this device a significant innovation for patients in the evaluation and treatment of coronary artery disease. In addition, continuing research will show whether the need to administer long-term dual anti-platelet therapy to patients is necessary once the temporary scaffold is metabolised.

The Absorb BVS received CE mark approval for the treatment of coronary artery disease and is under clinical investigation in several countries around the world.

About the ABSORB EXTEND clinical trial

The ABSORB EXTEND trial is a large-scale, single-arm trial that will enrol approximately 1,000 patients with complex coronary artery disease at up to 100 centres in Europe, Asia Pacific, Canada and Latin America.

Data from this trial may be used to support approval in various markets around the world. Key endpoints of the study include assessments of safety - major adverse cardiac events (MACE) and treated-site thrombosis rates - at 30 days and at six, 12, 24 and 36 months, as well as an assessment of the acute performance of the bioresorbable vascular scaffold, including successful deployment of the system. Other key endpoints in a sub-group study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other imaging modalities.

Add New Comment

Related Items

Most popular

“We all need the strength” to challenge unacceptable behaviour
Thursday, 20 Aug 2015
The editors of Annals of Internal Medicine have called for doctors to confront colleagues who act in a disrespectful manner towards patients after an anonymous essay in the journal highlighted ... “We all need the strength” to challenge unacceptable behaviour

FFRCT significantly reduces the number of invasive tests with no sign of obstructive disease
Tuesday, 01 Sep 2015
The PLATFORM study, which was presented at the ESC, indicates that use of FFRCT is associated with a significant reduction in the number of invasive tests that do not find evidence of obstructive ... FFRCT significantly reduces the number of invasive tests with no sign of obstructive disease

Tuesday, 25 Aug 2015
Medtronic has announced that it has signed a definitive agreement to acquire the company Twelve, which is focused on the development of a transcatheter mitral valve implantation (TMVI) device. Medtronic to buy company that is developing a transcatheter mitral valve implantation device


Further studies needed to find effective treatment for reperfusion injury
Wednesday, 07 Oct 2015
In this commentary, Michael Gibson reviews the various approaches that have been evaluated for reperfusion injury and states why he believes further studies in this area are still needed. Further studies needed to find effective treatment for reperfusion injury

Rediscovering the transfemoral approach for structural heart interventions
Monday, 14 Sep 2015
Before we abandon “the good old femoral route” completely, the advent of structural heart disease interventions means that we still have a use for the approach. Flavio Ribichini explores the use of ... Rediscovering the transfemoral approach for structural heart interventions


Javier Escaned
Wednesday, 02 Sep 2015
Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, M... Javier Escaned

Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions